Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.78 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.78 |
| ▸ | RAB9A | P51151 | 7/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.76 |
| ▸ | NPC1 | O15118 | 4/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 5/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.61 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113855 | 0.87 | RAB9A (0.79) | SAE1UBA2RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL11092496 | 0.87 | RAB9A (1.00) | SAE1UBA2RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4127845 | 0.87 | SAE1 (0.73) | SAE1UBA2RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL14462302 | 0.86 | SAE1 (0.78) | SAE1UBA2RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL19234508 | 0.85 | NPC1 (0.78) | RAB9ASMN1; SMN2NPC1LMNAMEN1 | |
| SCHEMBL13185621 | 0.85 | SMN1; SMN2 (1.00) | RAB9ASMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL13952165 | 0.85 | NPC1 (0.78) | RAB9ASMN1; SMN2NPC1LMNAMEN1 | |
| SCHEMBL4105709 | 0.85 | MAPT (0.73) | RAB9ASMN1; SMN2NPC1LMNAMEN1 | |
| SCHEMBL4105835 | 0.85 | SAE1 (0.76) | SAE1UBA2RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4124694 | 0.85 | MAPT (0.75) | SAE1UBA2RAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | claimed |
| EP-1804785-A2 | DIARYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2007-07-11 | — | — | EP | claimed |
| WO-2006049941-A2 | DIARYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-05-11 | — | — | WO | claimed |
| WO-2017136943-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2017-08-17 | — | — | WO | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | SAE1 2238/4885UBA2 318/4885RAB9A 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.